Uromonitor®在尿路上皮膀胱癌检测中的真实世界表现:一项多中心试验
这项多中心前瞻性双盲研究在德国四家泌尿中心2019至2024年开展,比较Uromonitor®与尿细胞学在尿路上皮膀胱癌诊断中的表现。Uromonitor®灵敏度49.3%、特异度93.3%,对尿细胞学灵敏度44.6%未显示统计学优势(P=0.316)。Uromonitor阳性对检出尿路上皮膀胱癌有显著预测价值(OR 9.03,P<0.001)。
要点
- Uromonitor®灵敏度49.3%、特异度93.3%、阳性预测值92.8%、阴性预测值51.1%、准确率65.2%。
- Uromonitor®灵敏度49.3% vs 尿细胞学44.6%,差异未达统计学显著(P=0.316)。
- Uromonitor阳性与检出尿路上皮膀胱癌独立相关(OR 9.03,P<0.001)。
核心结论
- Uromonitor®在此真实世界环境中未能证实既往研究预期的优越结果。
- 寻找检测和监测尿路上皮膀胱癌的最佳尿液生物标志物仍在继续。
- 本研究结果凸显开发非侵入性诊断工具的复杂性,并强调持续研究以改进这些技术的重要性。
研究设计与样本
- 多中心、前瞻性、双盲研究,2019至2024年在德国四家泌尿中心开展。
- 研究纳入尿路上皮膀胱癌患者与健康对照,在真实世界环境中评估Uromonitor®与尿细胞学的诊断表现。
- 评估灵敏度、特异度、阳性预测值、阴性预测值、准确率,并行多变量分析评估各原癌基因突变检测尿路上皮膀胱癌的能力。
- 生物统计学样本量设计旨在实现灵敏度10%的差异。
主要发现
- 尿路上皮膀胱癌患者占研究组的63.7%(339/532)。
- Uromonitor®的灵敏度49.3%、特异度93.3%、阳性预测值92.8%、阴性预测值51.1%、准确率65.2%,曲线下面积为0.713%。
- Uromonitor®灵敏度49.3% vs 尿细胞学44.6%,Uromonitor®未显示统计学优势(P=0.316)。
- 其他检测参数比较及多项敏感性分析比较均未显示两种尿液检测间有显著差异。
- 多变量logistic回归显示Uromonitor阳性对检出尿路上皮膀胱癌有显著预测价值(OR 9.03;P<0.001);TERT和FGFR-3突变分别与高尿路上皮膀胱癌检出 odds 独立相关(OR 13.30和7.04),KRAS突变未显示预测能力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare Uromonitor® (U-Monitor Lda, Porto, Portugal), a multitarget DNA assay that detects mutated proto-oncogenes (telomerase reverse transcriptase [TERT], fibroblast growth factor receptor 3 [FGFR-3], Kirsten rat sarcoma viral oncogene homologue [KRAS]), with urine cytology in the urine-based diagnosis of urothelial carcinoma of the bladder (UCB) within a multicentre real-world setting. PATIENTS AND METHODS: This multicentre, prospective, double-blind study was conducted across four German urological centres from 2019 to 2024. We evaluated the diagnostic performance of Uromonitor compared to urine cytology in a cohort of patients with UCB and in healthy controls within a real-world setting. Sensitivity, specificity, positive-predictive value (PPV), negative-predictive value (NPV), and accuracy of the tests were measured, in addition to multivariate analyses to assess the ability of individual proto-oncogene mutations in detecting UCB. The biometric sample size was designed to achieve a 10% difference in sensitivity. RESULTS: Patients with UCB comprised 63.7% (339/532) of the study group. Uromonitor showed a sensitivity, specificity, PPV, NPV, accuracy, and an area-under-the-curve of 49.3%, 93.3%, 92.8%, 51.1%, 65.2%, and 0.713%, respectively. These metrics did not demonstrate statistical superiority over urine cytology in terms of sensitivity (44.6%; P = 0.316). Moreover, the comparison of additional test parameters, as well as the comparison within various sensitivity analyses, yielded no significant disparity between the two urinary tests. Multivariate logistic regression underscored the significant predictive value of a positive Uromonitor for detecting UCB (odds ratio [OR] 9.03; P < 0.001). Furthermore, mutations in TERT and FGFR-3 were independently associated with high odds of UCB detection (OR 13.30 and 7.04, respectively), while KRAS mutations did not exhibit predictive capability. CONCLUSION: Despite its innovative approach, Uromonitor fell short of confirming the superior results anticipated from previous studies in this real-world setting. The search for an optimal urine-based biomarker for detecting and monitoring UCB remains ongoing. Results from this study highlight the complexity of developing non-invasive diagnostic tools and emphasise the importance of continued research efforts to refine these technologies.
引用
- Wolff I, Kravchuk AP, Wirtz RM, et al. Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial. BJU Int. 2024. PMID: 38923777. doi:10.1111/bju.16450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。